Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 2,191,594 shares of the company's stock, valued at approximately $218,020,000. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.09% of Merck & Co., Inc. at the end of the most recent quarter.
Other institutional investors also recently added to or reduced their stakes in the company. Napatree Capital LLC raised its stake in Merck & Co., Inc. by 13.0% during the fourth quarter. Napatree Capital LLC now owns 4,220 shares of the company's stock worth $420,000 after acquiring an additional 485 shares in the last quarter. Littlejohn Financial Services Inc. bought a new stake in shares of Merck & Co., Inc. in the 4th quarter worth about $2,080,000. Raab & Moskowitz Asset Management LLC lifted its holdings in Merck & Co., Inc. by 17.7% during the 4th quarter. Raab & Moskowitz Asset Management LLC now owns 56,307 shares of the company's stock valued at $5,601,000 after purchasing an additional 8,461 shares during the last quarter. Global Wealth Management Investment Advisory Inc. lifted its holdings in Merck & Co., Inc. by 102.2% during the 4th quarter. Global Wealth Management Investment Advisory Inc. now owns 45,057 shares of the company's stock valued at $4,482,000 after purchasing an additional 22,775 shares during the last quarter. Finally, Sumitomo Mitsui DS Asset Management Company Ltd boosted its position in Merck & Co., Inc. by 1.7% in the fourth quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 632,355 shares of the company's stock valued at $62,907,000 after buying an additional 10,332 shares in the last quarter. 76.07% of the stock is owned by institutional investors and hedge funds.
Merck & Co., Inc. Stock Down 1.8%
NYSE MRK traded down $1.42 during trading hours on Wednesday, reaching $76.17. 12,271,678 shares of the company's stock were exchanged, compared to its average volume of 12,567,486. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.15 and a current ratio of 1.36. The company has a market capitalization of $191.27 billion, a price-to-earnings ratio of 11.32, a price-to-earnings-growth ratio of 0.77 and a beta of 0.43. The company's 50-day moving average is $81.09 and its two-hundred day moving average is $91.05. Merck & Co., Inc. has a one year low of $73.31 and a one year high of $134.63.
Merck & Co., Inc. (NYSE:MRK - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The company reported $2.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.16 by $0.06. Merck & Co., Inc. had a net margin of 26.67% and a return on equity of 45.35%. The company had revenue of $15.53 billion during the quarter, compared to the consensus estimate of $15.59 billion. During the same quarter in the prior year, the firm earned $2.07 earnings per share. The firm's revenue was down 1.6% compared to the same quarter last year. On average, analysts forecast that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.
Merck & Co., Inc. Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Tuesday, July 8th. Stockholders of record on Monday, June 16th will be issued a $0.81 dividend. The ex-dividend date is Monday, June 16th. This represents a $3.24 dividend on an annualized basis and a dividend yield of 4.25%. Merck & Co., Inc.'s dividend payout ratio (DPR) is 47.16%.
Merck & Co., Inc. announced that its board has initiated a share buyback plan on Tuesday, January 28th that allows the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization allows the company to purchase up to 4.1% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company's leadership believes its shares are undervalued.
Analyst Upgrades and Downgrades
A number of equities research analysts have commented on MRK shares. Morgan Stanley decreased their price objective on shares of Merck & Co., Inc. from $113.00 to $106.00 and set an "equal weight" rating on the stock in a report on Wednesday, February 5th. TD Securities lowered Merck & Co., Inc. from a "buy" rating to a "hold" rating and cut their price target for the company from $121.00 to $100.00 in a research note on Monday, February 10th. Guggenheim reiterated a "buy" rating and issued a $115.00 price objective on shares of Merck & Co., Inc. in a research report on Thursday, April 17th. Cantor Fitzgerald cut Merck & Co., Inc. from an "overweight" rating to a "cautious" rating in a report on Tuesday, May 20th. Finally, BMO Capital Markets reduced their target price on shares of Merck & Co., Inc. from $105.00 to $96.00 and set a "market perform" rating on the stock in a research note on Wednesday, February 5th. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, seven have assigned a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Merck & Co., Inc. presently has an average rating of "Moderate Buy" and an average price target of $109.19.
Read Our Latest Analysis on Merck & Co., Inc.
Insider Transactions at Merck & Co., Inc.
In related news, SVP Dalton E. Smart III sold 4,262 shares of Merck & Co., Inc. stock in a transaction that occurred on Friday, April 25th. The stock was sold at an average price of $82.76, for a total value of $352,723.12. Following the sale, the senior vice president now owns 7,778 shares of the company's stock, valued at approximately $643,707.28. This trade represents a 35.40% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.09% of the stock is owned by insiders.
Merck & Co., Inc. Company Profile
(
Free Report)
Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.
Further Reading

Before you consider Merck & Co., Inc., you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck & Co., Inc. wasn't on the list.
While Merck & Co., Inc. currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report